This article summarizes current recommendations and the target populations to receive H1N1 vaccine once the vaccine supplies are released this fall.
O n July 29, 2009, the Advisory Committee on Immunization Practices (ACIP) voted on the following four recommendations for the use of novel HINI influenza vaccine this fall. The Centers for Disease Control and Prevention (CDC) and the U.S. Department of Health and Human Services usually adopt the recommendations of the ACIP. The CDC is continuing to develop and test a vaccine for HI N 1 influenza and has indicated that an HINI vaccine may be issued starting in October. Given the primary target populations recommended to receive this vaccine, planning is currently focused on elementary and secondary schools as well as school health nurses and local public health partners. Many communities are seeking assistance from nurses in other disciplines to implement vaccination campaigns. • Initial efforts should focus on novel HI N 1 influenza vaccination of as many individuals as possible in initial target groups.
Pregnant women. Household and caregiver contacts of children younger than 6 months. Please note: Although teach-
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Health care and emergency medical services personnel.
Children from 6 months through 18 years.
Persons aged 19 to 24 (this extended age group was recommended because of the high number of cases in this group, not because of severity of disease or complications).
Persons aged 25 through 64 years who have health conditions associated with higher risk conditions. • If novel HI N 1 vaccine demand exceeds availability initially, subgroups within target groups that should be prioritized until vaccine supply increases are: Pregnant women. Household and caregiver contacts of children younger than 6 months.
Health care and emergency medical services personnel having direct contact with patients or infectious materials.
Children 6 months through 4 years old.
Children with chronic health conditions younger than 19 years. • When vaccine availability is sufficient at the local level to routinely vaccinate initial target populations, in consultation with state and local health departments, vaccination against novel influenza AHINI is recommended for healthy adults age 25 through 64 years. • Vaccination should be offered to persons aged 65 or older once vaccination programs are capable of meeting demand for vaccination of younger age groups. • The recommendation to offer vaccine to individuals aged 65 or older might need to be reassessed as new epidemiologic, immunologic, or clinical trials data warrant and in the context of global need for novel HINI vaccines. • Vaccination with seasonal vaccine should begin as soon as seasonal vaccine is available for those aged 65 and older.
In addition, seasonal influenza vaccination should begin as soon as it is available for all groups currently recommended for seasonal vaccine. Seasonal and pandemic vaccines may be administered on the same visit.
Note: Organizers of large public clinics that rely on state-supplied seasonal flu vaccine should plan to hold those clinics in early October. • HINI vaccine supply and availability is projected to increase quickly over time, and vaccine should not be kept in reserve for later administration of the second dose.
The complete ACIP report can be accessed at www.cdc.gov/ vaccines/recs/acip/default.htm. The U.S. Department of Health and Human Services' website for HINl, avian, and pandemic flu information and preparation is www.flu.gov.
